NCT07135544View on ClinicalTrials.gov

A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 14, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 30, 2028

Conditions
Biliary Tract CancerBiliary Tract Cancer (CCA)
Interventions
DRUG

Adebrelimab combined with the GC regimen and Apatinib

Adebrelimab 1200mg, intravenous infusion, on day 1, repeated every 3 weeks; Gemcitabine 1000mg/m2, on days 1 and 8, every 3 weeks Cisplatin 50mg/m2, on day 1, every 3 weeks Apatinib 250mg, once daily, orally

Trial Locations (1)

430030

RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Yongjun Chen

OTHER

NCT07135544 - A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer | Biotech Hunter | Biotech Hunter